Novo Nordisk stops development of new insulin product

A phase I trial turned out to be the nail in the coffin for Novo Nordisk’s potential treatment combining a basal insulin with a cholesterol lowering substance.

Photo: Rolf Vennenbernd/AP/Ritzau Scanpix

Novo Nordisk has terminated the development of what could have ended up being a new insulin product, insulin 147, according to the Danish pharmaceutical firm’s financial report on Wednesday.

The decision comes after a phase I trial of the drug, and Novo Nordisk cites ”portfolio considerations” as the reason for ceasing the development. Whether the drug’s safety profile wasn’t as hoped or insulin 147 didn’t reach certain endpoints, or if other pipeline projects have showed more promise, is not disclosed in the report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs